From Discovery through Development
Certara's goal is to provide solutions in predictive science, communication and informatics that facilitate the elimination of barriers to bi-directional sharing of information. Learn More
Certara was formed by the acquisition of Tripos®, Pharsight®, and Simcyp, each with a primary focus on a key phase within the drug discovery and development cycle, to create a single company with a unique set of capabilities for modeling, analysis, and simulation that span early discovery through Phase IV clinical trials.
Established in 1979, Tripos was the first company to bring computer aided, scientific computational drug discovery capabilities to the pharmaceutical industry, subsequently continuing to help a broad range of pharmaceutical companies and research facilities successfully accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, chemical, research, food, flavoring and fragrance markets
Pharsight was formed in 1995 and is widely known for the WinNonlin PK/PD modeling and simulation software, originally developed in 1984, and now well established as the leading tool of its kind in the industry. Since then, Pharsight has developed a wide range of PK/PD and clinical trial modeling and simulation software that touches nearly every drug in development. Additionally, Pharsight Consulting Services is the world’s largest PK/PD consulting services team that supports regulatory compliant analysis and clinical study reports.
Simcyp Limited was founded in 2001 as a spin-out company from the University of Sheffield, UK. Through a pre-competitive consortium, Simcyp develops a user-friendly platform designed specifically to allow you to conduct simulations in representative virtual patient populations based on your in vitro and clinical data. The Simulator includes extensive demographic, physiologic and genomic databases which have allowed us to develop algorithms which account for patient variability. This enables the user to predict drug behavior in the virtual patient population, as opposed to a virtual reference man, allowing individuals at extreme risk to be identified.